BioXell announces change in management

BioXell announces change in management

Milan, Italy, 1 December 2009 - BioXell S.p.A. (SIX: BXLN) announced today the termination of the working relationship with Laurence H. Skillern, Chief Medical Officer.

Mr. Skillern joined BioXell as Chief Medical Officer as of February 1, 2009. His function has been terminated by both parties by mutual agreement effective November 30, 2009.

About BioXell BioXell S.p.A. (SIX: BXLN) is a listed biopharmaceutical company that focused on the discovery and development of drugs that exploit novel mechanisms of action. The Company is currently pursuing efforts to outlicense its monoclonal antibody BXL1H5 for the treatment of chronic pain. On 18 November 2009, BioXell announced that its Board of Directors supports the intended public takeover by Cosmo Pharmaceuticals S.p.A. The offer is expected to be launched in December 2009 and will be closed in March 2010.

BioXell was founded in 2002 as a spin-out from Roche. In June 2006, BioXell listed its shares on the main segment of the SIX Swiss Exchange. The Company is located in Milan, Italy.

More information on BioXell can be found at: www.bioxell.com

For further information, please contact:

BioXell Dynamics Group SA Alvise Sagramoso, Chief Administrative Officer Christophe Lamps Tel: 39 (0)2 210 49 550 Tel: 41 (0)22 308 62 22 Fax: 39 (0)2 700 59 926 Fax: 41 (0)22 308 62 36 [email protected] cla[email protected]

This press release can be downloaded at www.bioxell.com. Disclaimer This press release does not constitute or form part, or all, of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of BioXell, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of BioXell, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. BioXell disclaims any obligation to update these forward-looking statements to reflect future events or developments.

End of Message

bioXell S.p.A via Olgettina 58 Milan Italy

WKN: A0J3MW; ISIN: IT0004069933 ; Listed: Main Market in SIX Swiss Exchange;

 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.